Eli Lilly And Co (NYSE:LLY) has been assigned a $121.00 price target by stock analysts at Credit Suisse Group in a research report issued on Friday. The firm presently has a “hold” rating on the stock. Credit Suisse Group’s price target would indicate a potential downside of 5.69% from the company’s previous close.
A number of other equities research analysts have also commented on the company. UBS Group began coverage on Eli Lilly And Co in a research report on Wednesday. They issued a “buy” rating and a $74.51 price target for the company. Zacks Investment Research raised Eli Lilly And Co from a “sell” rating to a “hold” rating in a research report on Tuesday, March 19th. JPMorgan Chase & Co. began coverage on Eli Lilly And Co in a research report on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 price target for the company. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research report on Tuesday, February 26th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $115.68.
NYSE LLY opened at $128.30 on Friday. The firm has a market capitalization of $132.84 billion, a P/E ratio of 23.12, a P/E/G ratio of 2.58 and a beta of 0.33. Eli Lilly And Co has a 12 month low of $74.51 and a 12 month high of $130.75. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07.
In other news, SVP Stephen F. Fry sold 14,847 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the completion of the transaction, the senior vice president now owns 109,663 shares in the company, valued at approximately $13,506,095.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Insiders sold a total of 834,190 shares of company stock valued at $102,516,602 in the last 90 days. Corporate insiders own 0.11% of the company’s stock.
Several hedge funds have recently bought and sold shares of LLY. Athena Capital Advisors LLC bought a new position in shares of Eli Lilly And Co during the 4th quarter worth $26,000. Wakefield Asset Management LLLP bought a new position in shares of Eli Lilly And Co during the 4th quarter worth $27,000. Larson Financial Group LLC bought a new position in shares of Eli Lilly And Co during the 4th quarter worth $29,000. Ironwood Financial llc bought a new position in shares of Eli Lilly And Co during the 4th quarter worth $30,000. Finally, Acima Private Wealth LLC bought a new position in Eli Lilly And Co in the 4th quarter worth about $33,000. Institutional investors own 78.69% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Understanding Market Liquidity
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.